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RESEARCH ARTICLE
Design and implementation of a custom 
next generation sequencing panel for selected 
vitamin D associated genes
Katherine Angela Benson1* , Sourabh Chand2, Alexander Peter Maxwell1, Laura Jane Smyth1, Jill Kilner1, 
Richard Borrows3 and Amy Jayne McKnight1
Abstract 
Background: Biologically active vitamin D has an important regulatory role within the genome. It binds the vitamin 
D receptor (VDR) in order to control the expression of a wide range of genes as well as interacting with the epig-
enome to modify chromatin and methylation status. Vitamin D deficiency is associated with several human diseases 
including end-stage renal disease.
Methods: This article describes the design and testing of a custom, targeted next generation sequencing (NGS) 
panel for selected vitamin D associated genes. Sequencing runs were used to determine the effectiveness of the 
panel for variant calling, to compare efficiency and data across different sequencers, and to perform representative, 
proof of principle association analyses. These analyses were underpowered for significance testing. Amplicons were 
designed in two pools (163 and 166 fragments respectively) and used to sequence two cohorts of renal transplant 
recipients on the Ion Personal Genome Machine (PGM)™ and Ion S5™ XL desktop sequencers.
Results: Coverage was provided for 43.8 kilobases across seven vitamin D associated genes (CYP24A1, CUBN, VDR, GC, 
NADSYN1, CYP27B1, CYP2R1) as well as 38 prioritised SNPs. Sequencing runs provided sufficient sequencing quality, 
data output and validated the effective library preparation and panel design.
Conclusions: This novel, custom-designed, validated panel provides a fast, cost effective, and specific approach for 
the analysis of vitamin D associated genes in a wide range of patient cohorts. This article does not report results from 
a controlled health-care intervention.
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Background
Biologically active vitamin D (1,25-dihydroxyvitamin 
D) is involved in the regulation of gastrointestinal cal-
cium absorption and bone homeostasis [1]. A precursor 
(7-dehydrocholestrol) to active vitamin D is produced in 
the skin on exposure to ultraviolet B (UVB) radiation and 
is also found in certain foods such as oily fish and cheese 
[2]. Recent NICE guidelines recommend that pregnant 
and breastfeeding women, children ages 6  months to 
5 years, adults over 65 years or anyone who is not regu-
larly exposed to the sun should take a daily vitamin D3 
(cholecalciferol) supplement up to 10,000  IU [3, 4]. A 
wide range of enzymes are involved in the metabolism 
and activity of vitamin D. Cytochrome P450 enzymes 
including CYP27B1, CYP2R1 and CYP24A1 contribute 
to the hydroxylation steps.
In the kidney, 1-α-hydroxylase, encoded by CYP27B1 
converts 25-hydroxyvitamin D3 to 1,25-dihydroxyvita-
min D, directly affecting the circulating levels of active 
vitamin D. Polymorphisms within CYP27B1 have pre-
viously been associated with the development of type 1 
diabetes [5]. The GC gene encodes the vitamin D binding 
protein which has affinity for all vitamin D metabolites 
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[6]. Polymorphisms within GC have been associated with 
reduced 25-hydroxyvitamin D3 levels [7].
The VDR is a steroid receptor expressed in more than 
30 cell types [8]. VDR functions as a heterodimer with 
the retinoid X receptor (RXR) in the presence of vita-
min D to activate transcription of vitamin D controlled 
genes [9, 10]. This is one of the mechanisms by which 
1,25-dihydroxyvitamin D regulates the genome, but it has 
also been shown to affect the epigenome through chro-
matin modifiers and methylation changes [11]. It has 
been suggested that as much as 3% of the human genome 
is under some form of regulatory control by vitamin D 
[8, 12]. Two lymphoblastoid cell lines stimulated with 
1,25-dihydroxyvitamin D were used to generate a ChIP-
Seq genome-wide map, which identified 229 genomic 
regions differentially bound with VDR before and after 
treatment with active vitamin D [13]. Significant changes 
in gene expression after stimulation with 1,25-dihydroxy-
vitamin D were observed for gene loci such as IRF8 and 
PTPN2 which were not previously associated with vita-
min D regulation [13]. Selected vitamin D related SNPs, 
within genes associated with vitamin D metabolism, are 
outlined in Table 1 [14–22].
Although the cost of both whole genome and exome 
sequencing is falling, these technologies are not always 
cost effective for routine use in laboratories or large-scale 
population studies. The bioinformatic analysis and raw 
data storage space required for large scale sequencing 
projects is often prohibitive. As an alternative, research-
ers may opt to sequence targeted genetic regions using 
sequencing panels [23]. There are two central approaches 
to enrich for targeted DNA regions; solution hybridisa-
tion using oligo-nucleotide probes such as the Agilent 
SureSelect™ custom panels, or PCR enrichment such 
as Ion Torrent AmpliSeq™ panels. During this study an 
Ion AmpliSeq™ (http://www.ampliseq.com) customised 
panel was designed using the Ion AmpliSeq™ Designer 
online tool and primer pairs to enrich genomic regions 
known to be associated with vitamin D [14, 15]. This 
PCR enrichment method was used as it provides deep 
and even coverage over the small genomic regions of 
interest which were targeted in our study and delivers 
higher rates of on-target sequencing [24, 25]. In contrast, 
where larger regions such as the whole exome are being 
targeted, hybridisation methods are recognised to be 
more suitable due to a higher rate of uniformity [25]. A 
comprehensive list of all regions targeted by the panel is 
included in Table 1.
The Ion PGM™ desktop sequencer, released in 2010, 
is ideally suited to sequencing selected batches of ampli-
cons such as those used in AmpliSeq™ sequencing pan-
els [26]. Increases in sequencing throughput between the 
Ion 314™, Ion 316™ or Ion 318™ silicon chips used by the 
Ion PGM™ are due to differences in chip size and closer 
packing of wells. The Ion S5™ and Ion S5™ XL sequencers 
were released in 2015, offering increased speed of data 
analysis, new scalable sequencing chips and considerably 
reduced hands-on-time. The Ion S5™ XL uses Ion 520™, 
Ion 530™ and Ion 540™ chips. It has a larger processor 
and is therefore capable of producing results faster and 
with a higher throughput than the Ion S5™. Sequencing 
output using Ion Torrent sequencers will vary depending 
on the input material, read lengths, chemistry employed, 
and the type of chip used.
Vitamin D deficiency has been suggested to be a risk 
factor for chronic kidney disease (CKD) [27–29]. A meta-
analysis conducted in 2011 showed that higher vitamin 
D levels are associated with increased survival in CKD 
patients [30]. Increased activity of the renin-angiotensin 
system is strongly associated with CKD and diabetes [31]; 
vitamin D is a negative regulator of the renin-angiotensin 
system [12].
Many kidney transplant centres in the United King-
dom (UK) routinely prescribe vitamin D supplements for 
kidney transplant recipients [32]. The kidney transplant 
population is prone to vitamin D deficiency due to sev-
eral factors including avoidance of direct sunlight, dietary 
deficiency, renal impairment (limiting the activation of 
vitamin D because of reduced 1-alpha hydroxylation) and 
anti-rejection medication such as corticosteroids which 
are known to increase metabolism of vitamin D. Kidney 
transplant patients have an increased risk of skin cancers 
and so are encouraged to avoid direct sunlight, thereby 
reducing the vitamin D which these patients produce in 
response to UVB exposure [33]. A 2007 UK study which 
tracked vitamin D levels in 104 newly transplanted and 
140 long-term renal transplant recipients found that vita-
min D deficiency was present in the majority of investi-
gated patients [34]. Existing literature shows that vitamin 
D deficiency also increases risk of the development of the 
common renal transplant complication, new onset dia-
betes after transplantation (NODAT) [35, 36]. Vitamin D 
is known to increase insulin sensitivity and deficiency of 
vitamin D may also aggravate transplant-related insulin 
resistance [37]. A recent study by Keyzer and colleagues 
which included 435 stable renal transplant recipients 
demonstrated that low vitamin D levels were indepen-
dently associated with all-cause mortality and a more 
rapid decline in eGFR over time [38].
The aim of our study was to design, validate and apply 
a custom Ion AmpliSeq™ NGS panel targeting selected 
vitamin D associated genetic regions. As described, vita-
min D deficiency is strongly associated with chronic kid-
ney disease and NODAT. Therefore, the panel was tested 
in two renal transplant populations to demonstrate its 
efficacy and results compared between two sequencers.
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Table 1 Genetic regions included in the custom AmpliSeq™ vitamin D panel
This table describes the genomic regions targeted by the custom vitamin D panel
Type Name Chr Amplicon start and end point Amplicons Coverage Reason for missed coverage
Gene CUBN 10 143 0.89059
Gene CYP24A1 20 28 0.9426
Gene CYP27B1 12 21 0.9049
Gene CYP2R1 11 14 1
Gene GC 4 27 0.8084
Gene NADSYN1 11 34 0.9829
Gene VDR 12 39 0.901
SNP rs10741657 11 0 0 Repetitive region
SNP rs10875694 12 0 0 Repetitive region
SNP rs11168275 12 48272163–48272406 1 1
SNP rs11168287 12 48285285–48285546 1 1
SNP rs11168314 12 0 0 Repetitive region
SNP rs12721366 12 48245439–48245713 1 1
SNP rs12785878 11 1 1
SNP rs12794714 11 0 1
SNP rs1544410 12 48239730–48239989 1 1
SNP rs1989969 12 48277824–48278036 1 1
SNP rs2060793 11 0 0 Repetitive region
SNP rs2071358 12 48366302–48366575 1 1
SNP rs2107301 12 48255540–48255664 1 1
SNP rs2189480 12 48263731–48263939 1 1
SNP rs2228570 12 48272752–48272975 1 1
SNP rs2238135 12 48278010–48278284 1 1
SNP rs2238139 12 48256146–48256419 1 1
SNP rs2239181 12 48255772–48256045 1 1
SNP rs2239182 12 0 0 Repetitive region
SNP rs2298850 4 72614158–72614402 1 1
SNP rs2408876 12 48273431–48273704 1 1
SNP rs2544038 12 48215081–48215350 1 1
SNP rs2544043 12 0 0 Repetitive region
SNP rs3740165 10 0 1
SNP rs3782905 12 48266129–48266327 1 1
SNP rs3922882 12 48284784–48284997 1 1
SNP rs3923693 12 48337491–48337729 1 1
SNP rs4073729 12 48337000–48337176 1 1
SNP rs4303288 12 48336602–48336727 1 0.5 Repetitive region
SNP rs4646536 12 0 1
SNP rs4760674 12 0 0 Repetitive region
SNP rs6013897 20 0 0 Repetitive region
SNP rs6823 12 48362278–48362509 1 1
SNP rs7299460 12 48296145–48296402 1 1
SNP rs731236 12 48238644–48238859 1 1
SNP rs739837 12 48238171–48238400 1 1
SNP rs7974708 12 1 1
SNP rs7975232 12 1 1
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Methods
Blood derived DNA was used for this study which was 
stored at −20 °C. DNA was extracted using the salting out 
method. The cohorts used for testing of the panel were: 
(1) a cohort of kidney transplant recipients (n = 77) from 
Belfast, Northern Ireland; (2) kidney transplant patients 
(n = 93) in a Birmingham-based cohort who had vitamin 
D levels and oral glucose tolerance test (OGTT) results 
measured prospectively at three separate time points 
(immediately before transplant, 3 months post-transplant 
and 12 months post-transplant) [39]. The patient charac-
teristics for each cohort are summarised in Table 2. Vita-
min D levels were measured in batches at an accredited 
NHS hospital lab from samples frozen at −40  °C, using 
mass spectrometry for serum total 25-hydroxyvitamin D. 
Possible confounders for vitamin D levels such as the sea-
son on blood sampling, skin colour, extensive use of high 
protection sunscreens or covering with clothing were not 
accounted for in this study.
The Belfast cohort was sequenced using both the 
Ion PGM™ and the Ion S5™ XL sequencers in order to 
compare variant calling efficiency and technical sample 
preparation. Variants called differently between sequenc-
ers were further investigated using Sanger sequenc-
ing to determine which next generation sequencer had 
identified the variant correctly. In addition, an applied 
association analysis was undertaken to determine if the 
targeted variants were associated with vitamin D levels or 
NODAT in each of these cohorts.
At the time of listing for transplantation, all potential kid-
ney transplant recipients were asked for written informed 
consent (or consent from a parent or guardian in the case 
of children) for their data to be stored within the Kidney 
Transplant Database and used in projects in an anonymised 
form. Approval for use of this database was granted by 
Office for Research Ethics Committees Northern Ireland 
(ORECNI)—reference number ORECNI 12/NI/0178.
A total of 77 transplant recipients were included in this 
study from the Belfast renal transplant cohort. NODAT 
was defined in this cohort as the new requirement for oral 
hypoglycaemic agents or insulin as a result of post-trans-
plant hyperglycaemia. The average age of the included 
patients was 45 with an age range of 12–71 years. There 
were more male renal transplant recipients (n  =  50) 
than female recipients (n  =  27) which is consistent 
with the established statistics that men are more likely 
to develop end stage renal disease (ESRD) than women 
[40]. The Belfast cohort patients included in this study 
were of white ethnicity. The Birmingham renal trans-
plant cohort is more ethnically diverse and the patients 
included in this study reflect this. The average age of 
patients in this group was 44 years with an age range of 
17–71  years. NODAT was defined in the Birmingham 
cohort if (a) fasting glucose ≥7  mmol/L or 2  h OGTT 
was ≥11.1 mmol/L from day 7 onwards and persisted at 
the 3 month timepoint, (b) HbA1c ≥6.5% (48 mmol/mol) 
from 3  months onwards, or (c) requirement for institu-
tion of therapy for NODAT in which case OGTT was not 
undertaken (fasting clinic glucose was ≥7 mmol/L in all 
such patients). Seventy Caucasian patients with recorded 
data on NODAT status were included as a replication 
cohort for the Belfast group NODAT association analysis.
The custom vitamin D panel targeting genes (Table 1) 
and SNPs associated with vitamin D identified during 
previous research with collaborators in Birmingham was 
designed using the Ion AmpliSeq™ Designer™ online tool 
[14, 15]. Four of these targeted genes were chosen after 
their reported association with vitamin D insufficiency in 
a genome-wide association study published in the Lancet 
in 2010 (GC, NADSYN1, CYP2R1, and CYP24A1) [7]. In 
addition, a list of six genes which code for proteins which 
are established components of vitamin D metabolism 
(CYP27A1, GC, CYP2R1, VDR, CYP27B1 and CYP24A1) 
were chosen in light of a publication by Cooper and 
Table 2 Patient cohort characteristics
Cohort Belfast Birmingham vitamin D analysis Birmingham NODAT replication
Total individuals (n) 77 93 70
NODAT
 Cases [n(%)] 33 (43%) 18 (19%) 16 (23%)
 Controls [n(%)] 44 (57%) 75 (81%) 54 (77%)
Average age in years (range) 45 (17–71) 44 (17–71) 46 (17–71)
Sex
 Male [n(%)] 50 (65%) 56 (60%) 44 (63%)
 Female [n(%)] 27 (35%) 37 (40%) 26 (37%)
Average weight (kg) (range) 112 (82–164) 77 (49–132) 79 (50–132)
Race Caucasian Mixed ethnicity Caucasian
# Blood collections 1 3 3
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colleagues in 2011 [41]. This paper discussed inherited 
variation in vitamin D genes and their association with 
predisposition to type 1 diabetes [41]. These prior pub-
lications informed the list of seven genes included in 
the panel. A previous study by Nejentsev and colleagues 
identified VDR polymorphisms which are necessary to 
study common variation in populations from the Brit-
ish Isles; these important SNPs were also included in the 
panel [42]. The four classically genotyped SNPs (BsmI, 
FokI, TaqI, ApaI) were also contained within the panel 
for completeness. Further SNPs were selected from pre-
vious experimental work from our group completed in 
collaboration with colleagues from Birmingham [14]. 
As part of this research, in which the linkage disequi-
librium structure for vitamin D in a UK population and 
additional ancestries was elucidated, robust sequenc-
ing methods including Sequenom and Sanger sequenc-
ing were employed [14]. These regions include large and 
small genes and are representative of other regions of the 
genome which groups which may use the Ion AmpliSeq™ 
method to sequence. These chosen targets (including 
coding and untranslated regions and 50  bp exon region 
flanking for genes) were entered into the online tool to 
generate BED files. The resulting amplicons were divided 
by the online designer into two primer pools to maximise 
target specificity.
These experiments employed early access reagents for 
the Ion S5™XL System, and Ion AmpliSeq™ technology, 
from Thermo Fisher Scientific. Libraries were prepared 
using the Ion AmpliSeq™ library kit 2.0 according to 
the manufacturer’s instructions. Genomic DNA (20  ng/
sample) was used for the initial PCR reactions. Samples 
were diluted no more than 4  h prior to sequencing to 
prevent DNA degradation. The Ion Chef™ or Ion One 
Touch™ and ES™ were used for emulsion PCR and tar-
get enrichment. The Ion PGM™ was used with Ion 318 
V2™ or Ion 316 V2™ chips to sequence the renal trans-
plant cohorts. The Belfast kidney transplant recipients 
were re-sequenced using the Ion S5™ XL sequencer 
on Ion 530™ chips. Reported SNPs from the Ion Tor-
rent sequencing runs on the Belfast kidney transplant 
cohort were compared between the two next generation 
sequencers. Variants found on one sequencer, but not the 
other, were then re-sequenced using Sanger sequencing. 
If possible, a sample which was reported with the variant 
on both sequencers, a sample which was reported as not 
having the variant on both sequencers and the sample in 
which the discrepancy was identified were also Sanger 
sequenced.
An overview of the analysis workflow is illustrated in 
Fig.  1. Preliminary analysis was conducted automati-
cally on the Ion Torrent Suite™ Version 4 where data was 
aligned to hg19.p5. Variant caller files generated from 
this analysis were used to compare the results between 
the Ion PGM™ and Ion S5™ XL sequencers. Sequencing 
data in the form of.bam files were further analysed using 
Partek Genomics Suite™. SNPs were identified using 
dbSNP Version 138 and annotated using RefSeq Ver-
sion 2015-08-04. The resulting variant files from Partek 
Genomics Suite™ were used for association analysis.
To complete the association analysis,.ped files were 
generated for use with PLINK software Version 1.07. An 
unadjusted genotype association test for trend was used 
to find associations between NODAT status and the tar-
geted variants in the Belfast renal transplant cohort using 
a P value threshold of 0.05. This P value is reported in this 
manuscript as Ptrend Variants with Hardy–Weinberg equi-
librium (HWE) <1 × 10−5 were removed from the analy-
sis. In previous studies, transplant recipient age and body 
mass index (BMI) were shown to be important risk fac-
tors for the development of NODAT [43–46]; these varia-
bles were included in the regression model (PLR). Changes 
in vitamin D levels at 3 and 12  months after transplant 
were evaluated for association with gene variants in the 
Birmingham kidney transplant cohort regarding vitamin 
D levels post-transplant as a quantitative trait (Ptrend). As 
with the association analyses in the Belfast cohort, vari-
ants with a minor allele frequency (MAF) of <0.05 or a 
Hardy–Weinberg equilibrium (HWE) <1  ×  10−5 were 
removed from the analysis. Recipient age and weight at 
transplant was included in this regression model (PLR). In 
addition, the association between NODAT and the iden-
tified gene variants was investigated in a subset of the 
Birmingham cohort (n = 70). All modelling assumed an 
additive inheritance pattern.
Sanger sequencing data was analysed using Vector NTI 
Advance™ Version 11.5.1. The resulting data files were 
aligned using Contig Express™ against the GRCh38 refer-
ence genome obtained from the Ensembl online resource 
(Version 8.4) [47]. The resulting chromatograms were 
visually inspected to determine whether the variant was 
identified correctly using NGS.
Results
Targeted SNPs, along with translated and untranslated 
regions for seven genes associated with vitamin D regu-
lation were successfully included in the custom panel 
(90.58% total coverage; 43.76  kb; Table  1). The targeted 
SNPs were shown in previous publications to be impor-
tant in Caucasian populations for vitamin D metabolism 
and regulation and were located within the seven chosen 
genes [42]. Amplicons were automatically split between 
two pools containing 163 and 166 amplicons. These indi-
vidual amplicons were 124–274 bp in length with an aver-
age size of 207 bp. PCR primers used in Ion AmpliSeq™ 
kits provided a high level of specificity and simplicity.
Page 6 of 15Benson et al. BMC Res Notes  (2017) 10:348 
Analysis on the Ion Torrent Suite™ included determi-
nation of the Ion Sphere Particle (ISP) loading, the num-
ber of usable reads and the length of sequencing reads for 
each run. Figures 2 and 3 show representative sequenc-
ing statistics for sequencing runs performed on the Ion 
PGM™ and Ion S5™ XL sequencers respectively.
Additional analysis was performed using plug-ins 
including variant caller, coverage analysis, and file 
exporter. Coverage was calculated using the coverage 
analysis plug-in, and representative plots are shown in 
Fig.  4. The hands on time required for the Ion PGM™ 
(approximately 1–1.5 h) was considerably higher than for 
the Ion S5™ XL (approximately 15 min) (Fig. 1).
A summary of the maximum output statistics for the 
sequencing chips from the NGS runs completed on the 
Ion PGM™ and Ion S5™ XL are shown in Table 3. Nine 
of the 11 sequencing runs were completed on the Ion 
PGM™ and two were completed on the Ion S5™ XL. Sim-
ilar percentages of usable reads were obtained from all 
comparable runs. Polyclonal levels varied depending on 
the dilution factor used following library preparation and 
had a marked impact on the percentage of usable reads. 
These polyclonal levels increased with respect to the 
level of DNA input. The sequencing output varied from 
429 Mb to 3.22 Gb and the total number of reads was rel-
atively consistent ranging from 2,755,634 to 80,308,654. 
Fig. 1 Overview of data analysis workflow. This image provides an overview of the described laboratory and analyses processes
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These data obtained for the two different cohorts were 
comparable although those obtained using the Ion 
PGM™ were significantly lower than those obtained 
using the Ion S5™ XL.
Based on the maximum output achieved by each of 
the different chip types used in this study, we observed a 
1.6 fold increase between data output from the Ion 316™ 
and Ion 318™ sequencing chips and a 4.8 fold increase 
between the Ion 318™ and Ion 530™ sequencing chips 
(Table 3).
Libraries for the Belfast renal transplant cohort were 
sequenced on both the Ion PGM™ and Ion S5™ XL. Due 
to the higher capacity of the Ion 530™ chip both ampli-
con pools were combined on the same sequencing chips 
for the Ion S5™ XL sequencing runs. Twenty-three SNPs 
were identified from the variant caller plug-in on the 
Ion Torrent Suite™ on one sequencer but not the other. 
Sanger capillary sequencing was used to determine 
which SNPs were genuine using 14 sets of PCR primers. 
Sanger sequencing is regarded as the gold standard for 
variant identification [48]. The SNP locations in sam-
ples with and without the proposed variants were visu-
ally inspected using Contig Express™. The Ion S5™ XL 
correctly identified nucleotide bases more often than 
the Ion PGM™ at these discordant SNP calls locations. 
Representative examples of the visual inspection of these 
Fig. 2 Sequencing statistics from an Ion PGM™ sequencing run. This 
figure demonstrates the loading density, read length histogram and 
summary statistics obtained from the Ion Torrent Suite™ following a 
representative Ion PGM™ sequencing run
Fig. 3 Sequencing statistics from an Ion S5™ XL sequencing run. This 
figure demonstrates the loading density, read length histogram and 
summary statistics obtained from the Ion Torrent Suite™ following a 
representative Ion S5™ XL sequencing run
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SNPs using Partek Genomics Suite™ for NGS results 
and Contig Express™ for Sanger sequencing results 
are shown in Figs. 5, 6, 7, 8, 9. The alleles with ambigu-
ous calls were identified correctly prior to association 
analysis.
The data obtained from the sequencing runs outlined 
in Table 3 was analysed on Partek Genomics Suite™ and 
used to perform association analysis to demonstrate the 
efficacy of the custom panel. Following analysis on Partek 
Genomics Suite™, off target and low coverage (less than 
30 fold) SNPs were removed along with SNPs identified 
as incorrect following Sanger sequencing.
Initially, the association between development of 
NODAT post-renal transplant and the vitamin D vari-
ants in the panel was investigated in the Belfast kidney 
transplant population. In total, 457 SNPs were included 
for analysis from sequencing data obtained using the 
Ion S5™ XL. The top hits from this genotype associa-
tion analysis using a nominal significance threshold of 
Ptrend  <  0.05 along with the corresponding results of 
the regression analyses are shown in Additional file  1: 
Table S1.
The association between NODAT development and 
the target variants was also investigated in a subset of the 
Birmingham kidney transplant cohort (n  =  70) which 
included 16 NODAT cases and 54 renal transplant con-
trols. The top hits are shown in Additional file  1: Table 
S2 along with the results of the regression analysis. 
In total, nine variants were nominally associated with 
NODAT development in the Birmingham cohort at the 
Ptrend  <  0.05 significance threshold in the genotypic test 
for trend. One variant was nominally associated with 
NODAT status in both the Belfast and Birmingham 
cohorts (rs1801239).
The association between the changes in vitamin D lev-
els 3 or 12 months following renal transplant and the var-
iants targeted on the custom panel were investigated in 
the Birmingham kidney transplant cohort (n = 93). The 
results of these analyses are shown in Additional file  1: 
Table S3 using a genotype test for trend with a thresh-
old of Ptrend < 0.05. Variants with a MAF of less than 0.05 
or a HWE P value of less than 1 ×  10−5 were removed 
from this analysis. No variants retained significance after 
adjustment for multiple comparisons.
Fig. 4 Representative coverage plots from a Ion S5™ XL and b Ion PGM™ sequencing runs. Both a and b show the consistent, high coverage levels 
obtained from both Ion S5™ XL and Ion PGM™ sequencing runs respectively. The Ion S5™ XL obtained slightly higher sequencing coverage (A)
Table 3 Sequencing runs completed using both the Ion PGM™ and Ion S5™ XL
Libraries were prepared using 20 ng genomic DNA. Dilution factors chosen for the sequencing runs were either 26 or 50 pM depending on the number of samples to 
be sequenced and the level of coverage desired
Sequencing Runs per chip
Sequencer Chip type Dilution (pM) Preparation Max. output Samples Usable reads (%) Max. reads Polyclonal (%)
Ion PGM™ Ion 316™ 26 Ion Chef™ 429 Mb 8–12 51–57 2,755,634 21–37
Ion PGM™ Ion 318™ 26/50 Ion Chef™/Manual 668 Mb 48–96 48–50 4,880,500 11–40
Ion S5™ XL Ion 530™ 50 Ion Chef™ 3.22 Gb 85 50–61 80,308,654 26–30
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Fig. 5 NGS and Sanger sequencing results at chromosome 4, location 72611690. A tri-allelic variant was identified at this locus. The variant was 
reported by the Ion S5™ XL variant caller file but not the Ion PGM™ variant caller file despite appearing in both in Partek Genomics Suite™ (on left). 
Sanger sequencing on the right for sample LT1308 as well as two other samples (LT744, LT120) shows that sample LT1308 is a T/C heterozygote 
while sample LT744 is G/G and sample LT120 is C/C
Fig. 6 NGS and Sanger sequencing results at chromosome 10, location 16911556. At this locus, a heterozygote G/T variant was called in sample 
LT1308 by the Ion S5™ XL but not the Ion PGM™. Visual inspection of the Sanger sequencing results (shown here on the reverse strand) determined 
that the variant had been called incorrectly. There is a peak shown for A which matches the reference sequence. It is likely that the homo-polymer 
region was the reason the Ion S5™ XL had difficulty reporting this SNP
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Fig. 7 NGS and Sanger sequencing results at chromosome 11, location 71174553. Sample LT744 shown in Partek on the left of this figure, was 
reported to have a heterozygous C/T SNP at position chr11:71174553. This was detected by the Ion S5™ XL but not the Ion PGM™. Sanger sequenc-
ing results shown on the right of the figure confirmed that sample LT744 has a C/T SNP at this locus which is not present in sample LT120
Fig. 8 NGS and Sanger sequencing results at chromosome 12, location 48237736. The reference genome here shows an A base at locus 
chr12:48237736. The Ion S5™ XL reported a G/G variant. Sanger sequencing confirmed that there was a deletion at this locus in sample RT482 fol-
lowed by five G bases. This deletion is not shown in sample LT744 which is also shown in the Sanger sequencing results on the right of this figure
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Discussion
This study demonstrated the successful application of 
a customised vitamin D targeted NGS panel in two 
renal transplant cohorts. The library preparation pro-
cedure successfully enriched for the targeted genomic 
regions designed using the Ion AmpliSeq™ designer tool. 
Sequencing runs provided sufficient sequencing quality, 
data output and validated the effective library prepara-
tion and panel design. The panel achieved sufficient (>30 
fold) coverage to reliably identify variants associated with 
vitamin D metabolism and regulation. The representative 
coverage maps shown in Fig. 4 demonstrated that similar 
coverage patterns were obtained using both sequencers 
which confirms the consistency of the targeted panel.
The Ion Torrent Suite™ indicated that the overall quality 
of the data obtained from sequencing runs on the Ion S5™ 
XL was better than the data quality from sequencing per-
formed on the Ion PGM™. For example, the bead loading 
onto the silicon chips was higher in runs performed on 
the Ion S5™ XL as shown in Figs. 5, 6 and 7. Higher lev-
els of data output were achieved when the panel was used 
on the Ion S5™ XL rather than the Ion PGM™ as shown 
by the sequencing statistics in Table 2. These differences 
are almost certainly due to the chip type employed dur-
ing the sequencing runs. The Ion 530™ chip used in this 
study has an inherently higher capacity (~38 million wells 
per chip) than the Ion 316™ (~6 million wells per chip) or 
Ion 318™ chips (~11 million wells per chip). Higher chip 
capacity allows more samples to be included on the same 
chip with higher coverage for each sample. The number 
of samples and coverage level can be balanced when plan-
ning a sequencing run to achieve optimum results.
In addition to larger sample capacity and higher cov-
erage potential on the Ion S5™ XL, this sequencer was 
demonstrated to identify variants correctly more often 
than the Ion PGM™. When variants called differently on 
both sequencers were investigated by Sanger sequenc-
ing, it was determined that the Ion S5™ XL was correct in 
14 instances while the Ion PGM was correct nine times. 
The Ion S5™XL did call slightly higher numbers of cor-
rect variants than the Ion PGM™. Despite the differences 
between the sequencers, the majority of reported results 
were consistent between both machines which is evi-
dence that this custom panel is effective and reliable.
Association analyses were conducted to demonstrate 
the efficacy and potential applications of the custom 
NGS panel. These analyses were conducted in two kid-
ney transplant cohorts to investigate the association 
between the targeted variants and either changes in 
vitamin D levels post-transplant or the development of 
NODAT, a serious post-transplant complication. None of 
the variants identified in the presented analyses reached 
Fig. 9 NGS and Sanger sequencing results at chromosome 20, location 52789779. The Partek figure on the left shows a C/A variant in sample RT106 
identified in pool 2 of the Ion PGM™ sequencing results. This was not called by the Ion S5™ XL. Sanger sequencing on the right confirmed that 
there is no variant at this locus in either sample RT106 or sample LT744. A single peak is shown for C in both of these samples (the Sanger sequenc-
ing image to the right of this image is shown in the reverse complement). These results confirm that the Ion PGM™ called this variant incorrectly
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genome-wide significance thresholds due to the small 
number of samples included. This was expected as these 
analyses were designed to provide proof-of-concept and 
were not intended to represent a well powered genotype 
association study. Hence, no adjustments for multiple 
testing have been made in the presented results.
The Belfast renal transplant cohort was used to inves-
tigate the association of NODAT with these vitamin D 
related regions on the custom panel. The results pre-
sented in Additional file  1: Table S3 show the nominal 
association of the NODAT phenotype at the Ptrend < 0.05 
threshold in a genotype association test for trend.
Two missense mutations (rs1801240 and rs1801239) in 
the CUBN gene exon 57 were nominally associated with 
NODAT following this analysis. These mutations are in 
strong linkage disequilibrium as shown by the Haploview 
image in Fig. 10 (D’ = 1.0, 95% CI 0.89–1.0). An article 
by Tzur and colleagues has previously described a hap-
lotype characterised by CUBN exon 57 and 42 SNPs 
including these variants [49]. Tzur associated this hap-
lotype with an increased incidence of albuminuria [49]. 
Proteinuria post-transplant is a known risk factor for 
NODAT and if the patients were predisposed to albumi-
nuria this may have in part contributed to the develop-
ment of the NODAT transplant complication. A subset 
of the Birmingham renal transplant cohort was used to 
replicate these analyses (Additional file  1: Table S2). 
Notably, rs1801239 was also identified in this cohort. The 
variant rs1801239 had a similar direction of effect follow-
ing logistic regression in the previous GWAS (OR: 3.904; 
PLR: 0.001; 95% CI 1.7–8.8). It is important to note that 
none of the highest ranking variants identified in this 
analysis association analysis were identified in a previ-
ous genome wide association study (GWAS) conducted 
in the same Northern Irish renal transplant population 
[46]. In addition, none of variants in the exon 57 and 42 
regions of the CUBN gene covered on the GWAS panel 
were associated with NODAT in this previous study at 
the genome-wide significance threshold.
In the Birmingham renal transplant cohort, the asso-
ciation between change in vitamin D levels after kidney 
transplantation and the variants on the custom panel 
was investigated. The results of these analyses are shown 
in Additional file 1: Table S3. Three SNPs were found in 
common between the analyses of vitamin D change at 3 
and 12 months including two variants in the promoter 
rank region of CYP27B1.
The seasonality of testing for vitamin D levels was not 
considered during this study. This is a potential limita-
tion, but this study involved renal transplant recipients 
who are known to have an inherently higher risk of skin 
malignancy associated with immunosuppression and are 
therefore advised to use high factor sunscreens and to 
stay out of direct sunlight [50, 51]. There clinical factors 
would be likely to reduce the impact of seasonality on the 
vitamin D levels in these individuals.
Most of the associated variants, using data from both 
sequencers and in both cohorts, were in the cubilin 
(CUBN) gene. This gene encodes the peripheral mem-
brane protein cubilin which contributes to the uptake of 
vitamin B12 and metabolism of vitamin D [52]. A previ-
ous study demonstrated that patients with non-function-
ing cubilin lose significant amounts of 25-hydroxyvitamin 
D3 in their urine, reducing their plasma 1,25-dihydroxy-
vitamin D levels [22]. Cubilin is essential for the reab-
sorption of proteins in the proximal tubules of the kidney 
[53]. A study published in 2012 investigated the associa-
tion between variants in the CUBN gene and graft fail-
ure in renal transplant recipients [54] following a GWAS 
which linked these variants to albuminuria [55, 56]. The 
Fig. 10 Haploview™ image of SNPs rs1801240 and rs1801239. This image shows that these two missense mutations identified by the Ion S5™ XL 
are tightly linked (strong linkage disequilibrium is indicated by the red diamond)
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study found that the CUBN variant rs7918972 in the 
organ donor genotype was associated with graft failure 
in the transplant recipient population. It is important to 
note that the CUBN gene is large (0.31 mega-bases) and 
so it is possible that the large number of variants identi-
fied in this gene in the presented study may be a result of 
the size of the gene rather than a of true association with 
the investigated phenotype. Larger genes will naturally 
harbour more variants than smaller genes included on 
the panel. It is important to account for this by applying 
P value threshold which accounts for multiple testing in 
further well powered studies [57].
The association analysis performed on these cohorts 
using data from two different sequencers demon-
strates the capacity of the custom panel to detect SNP 
associations. To gain more statistically significant and 
meaningful associations the panel should be applied to 
considerably larger cohorts. This NGS panel will allow 
collaborating laboratories to perform identical targeted 
sequencing for vitamin D associated genomic regions. 
Studies that demonstrate significant associations between 
the phenotype of interest because of investigations using 
this targeted panel, will require further analysis using 
functional studies to explore the mechanisms underpin-
ning the associations.
Sanger sequencing is costly when focusing on many 
variants or genes such as those targeted in this panel. 
Sanger sequencing is also more time consuming than 
NGS techniques which offer a higher throughput 
approach to variant detection. Targeted NGS panels 
such as this custom AmpliSeq™ panel offer an attractive 
alternative to Sanger sequencing for projects encom-
passing larger numbers of target variants. Whole exome 
sequencing is a popular alternative to custom NGS pan-
els but this approach is more expensive than targeted 
panels. The larger volume of sequencing data produced 
by exome sequencing requires more storage space and 
bioinformatic analysis which can be associated with sig-
nificant costs. Incidental findings are also a more signifi-
cant issue when using whole exome sequencing.
This NGS panel represents a cost effective, fast molecu-
lar test with minimal hands on time. This high throughput 
panel can be used to sequence one pool of 96 amplicons 
on a single Ion 318™ chip. The Belfast renal transplant 
cohort in contrast has more limited genetic heterogeneity 
with a very tightly defined NODAT phenotype. It is vital 
to note that the association results presented in this study 
are primarily demonstrating proof-of-principle that this 
NGS panel can be effectively applied to a range of vary-
ing populations rather than trying to establish definitive 
evidence of associations. The patient numbers included 
in these cohorts do not provide enough power to reliably 
identify associations with small to moderate effect sizes, 
but do confirm the utility of the panel. Despite these lim-
itations, this reliable and cost effective vitamin D panel 
was successfully used to sequence the targeted vitamin D 
regions in two renal transplant populations with excellent 
coverage and successful variant calling.
Homo-polymer regions are one of the limiting factors 
in any project relying on Ion Torrent™ sequencers which 
tend to underestimate or overestimate the length of 
repeated, identical base calls. A previous study reported 
that 94–97% of total error on the Ion PGM™ was due 
to homo-polymer regions [58]. During this study, these 
regions were indeed shown to have a high error rate. 
Most of the discrepancy variants investigated by Sanger 
sequencing were close to these repetitive regions, such 
as the DNA fragment shown in Fig.  6. The design of 
the panel itself was also shaped by these homo-polymer 
regions. Table  1 shows that some regions could not be 
covered by the panel due to repetitive regions in the tar-
get sequences.
Conclusions
During the course of this study, a custom NGS panel 
was designed, implemented and validated. Two separate 
kidney transplant cohorts were used to demonstrate the 
potential of the panel and to verify the effectiveness of 
this targeted NGS approach. The custom panel success-
fully targeted genomic regions putatively involved in vita-
min D regulation.
A comparison of the targeted panel using the Ion 
PGM™ and Ion S5™ XL sequencers from the Ion Torrent 
range was performed during this study. This was achieved 
by comparing the variants identified by the Ion Torrent™ 
variant caller plug-in following runs of the same panel on 
the two sequencers. The results of this analysis showed 
that the Ion S5™ XL identified more variants, with higher 
accuracy than the Ion PGM™ in comparable runs. There-
fore, although the panel was effective on both sequenc-
ers, the inherent advantages of the Ion S5™ XL provided 
clear improvements in performance over the Ion PGM™.
Proof-of-concept association analyses were performed 
using the sequencing data obtained using the custom NGS 
panel. It is possible that the mutations in vitamin D linked 
to change in vitamin D levels after kidney transplantation 
or to NODAT in these analyses are valuable. However, the 
aim of the analysis was to demonstrate the use of the cus-
tom NGS panel rather than undertaking comprehensive 
associations with gene variants in these cohorts. In order 
to further elucidate the link between these variants and 
the phenotypes investigated here, larger scale association 
studies are necessary alongside functional studies, par-
ticularly as change in BMI was included in the covariate 
model. This work could lead to further understanding of 
the pathways involved in the development of NODAT for 
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example, leading to treatments and perhaps diet and life-
style recommendations which are better tailored to indi-
viduals with certain genetic profiles.
Overall, this study has demonstrated the effectiveness 
of this novel, targeted NGS panel for genomic regions 
putatively involved in vitamin D regulation and metabo-
lism. This panel has a wide range of potential applications 
and will be valuable to an assortment of future projects.
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